C. Haanen

11.7k total citations · 2 hit papers
199 papers, 9.6k citations indexed

About

C. Haanen is a scholar working on Hematology, Molecular Biology and Genetics. According to data from OpenAlex, C. Haanen has authored 199 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 81 papers in Hematology, 55 papers in Molecular Biology and 38 papers in Genetics. Recurrent topics in C. Haanen's work include Acute Myeloid Leukemia Research (41 papers), Acute Lymphoblastic Leukemia research (31 papers) and Hematopoietic Stem Cell Transplantation (28 papers). C. Haanen is often cited by papers focused on Acute Myeloid Leukemia Research (41 papers), Acute Lymphoblastic Leukemia research (31 papers) and Hematopoietic Stem Cell Transplantation (28 papers). C. Haanen collaborates with scholars based in Netherlands, Germany and Italy. C. Haanen's co-authors include I. Vermes, Chris Reutelingsperger, P A Speth, Q.G.C.M. van Hoesel, T. de Witte, Albertus Beishuizen, H. Wessels, R. S. G. Holdrinet, P. Linssen and J.M.C. Wessels and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Blood.

In The Last Decade

C. Haanen

193 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A novel assay for apoptosis Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V

1995 4.7k citations I. Vermes, C. Haanen et al. profile →
Flow cytometry of apoptotic cell death

2000 652 citations I. Vermes, C. Haanen et al. profile →

Peers

Countries citing papers authored by C. Haanen

Since Specialization

Citations

This map shows the geographic impact of C. Haanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Haanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Haanen more than expected).

Fields of papers citing papers by C. Haanen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Haanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Haanen. The network helps show where C. Haanen may publish in the future.

Co-authorship network of co-authors of C. Haanen

This figure shows the co-authorship network connecting the top 25 collaborators of C. Haanen. A scholar is included among the top collaborators of C. Haanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Haanen. C. Haanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sequential occurrence of mitochondrial and plasma membrane alterations, fluctuations in cellular Ca2+ and pH during initial and later phases of cell death 1999 ·APOPTOSIS ·(unknown), Mehmet YİLDİRİM, Chris Reutelingsperger, C. Haanen, I. Vermes	13
2	Apoptosis- and necrosis-inducing potential of cladribine, cytarabine, cisplatin, and 5-fluorouracil in vitro: a quantitative pharmacodynamic model 1998 ·Cancer Chemotherapy and Pharmacology ·Henk‐Jan Guchelaar, I. Vermes, Richard P. Koopmans, Chris Reutelingsperger, C. Haanen	59
3	Early Features of Apoptosis Detected by Four Different Flow Cytometry Assays 1998 ·APOPTOSIS ·(unknown), (unknown), I. Vermes, Chris Reutelingsperger, C. Haanen	97
4	1997 ·Pharmacy World & Science ·Henk‐Jan Guchelaar, András Vermes, I. Vermes, C. Haanen	69
5	A long-lasting, complete hematologic and cytogenetic remission of chronic myelogenous leukemia after treatment with busulfan alone 1996 ·Annals of Hematology ·(unknown), E. J. B. M. Mensink, Ad Geurts van Kessel, D. C. van der Plas, C. Haanen, (unknown), T. de Witte	1
6	Cell cycle kinetics of hematopoiesis before and after in vivo administration of GM-CSF in refractory anemia: Evidence for a shortening of the granulocyte release time 1994 ·Annals of Hematology ·Paul Brons, Nico van der Lely, C. Haanen, A. Pennings, J.B.M. Boezeman, J.M.C. Wessels, (unknown), T.J.M. de Witte	2
7	Elevated plasma levels of endothelin are associated with the severity of sepsis and presence of shock in contrast to the levels of atrial natriuretic peptide 1992 ·Mediators of Inflammation ·(unknown), (unknown), (unknown), C. Haanen, (unknown)	5
8	1-β-D-arabinofuranosylcytosine (Ara-C) enhances mitochondrial activities in human leukaemic cells 1991 ·British Journal of Cancer ·Petra Muus, Coby Van den Bogert, H. de Vries, A. Pennings, Marijke Holtrop, C. Haanen	14
9	Phenotypic and Functional Changes of Tumour Cells from Patients Treated with Monoclonal Anti‐Idiotypic Antibodies 1990 ·Scandinavian Journal of Immunology ·Wil A. Allebes, Ruth Knops, Ronald E. Bontrop, Ńel Otting, (unknown), C. Haanen, P J Capel	5
10	Thrombotic thrombocytopenic purpura: clinical course and response to therapy in twelve patients. 1988 ·PubMed ·(unknown), (unknown), C. Haanen	2
11	The development of non-responsiveness to immunotherapy with monoclonal anti-idiotypic antibodies in a patient with B-CLL 1988 ·British Journal of Haematology ·Wil A. Allebes, Frank Preijers, C. Haanen, P J Capel	6
12	Clinical Pharmacokinetics of Doxorubicin 1988 ·Clinical Pharmacokinetics ·P A Speth, Q.G.C.M. van Hoesel, C. Haanen	351
13	Mitochondrial biogenesis and mitochondrial activity during the progression of the cell cycle of human leukemic cells 1988 ·Experimental Cell Research ·Coby Van den Bogert, Petra Muus, C. Haanen, A. Pennings, (unknown), A.M. Kroon	45
14	Different Susceptibilities of Normal T Cells and T Cell Lines to Immunotoxins 1988 ·Scandinavian Journal of Immunology ·Frank Preijers, W.J.M. Tax, J.M.C. Wessels, P J Capel, T. de Witte, C. Haanen	21
15	Determination of amsacrine in human nucleated hematopoietic cells 1987 ·Journal of Chromatography B Biomedical Sciences and Applications ·Paul Brons, J.M.C. Wessels, P. Linssen, C. Haanen, P A Speth	8
16	Cellular and plasma adriamycin concentrations in long-term infusion therapy of leukemia patients 1987 ·Cancer Chemotherapy and Pharmacology ·(unknown), (unknown), (unknown), (unknown), C. Haanen	69
17	Factor XI Kinetics after Plasma Exchange in Severe Factor XI Deficiency 1986 ·Pathophysiology of Haemostasis and Thrombosis ·I.R.O. Nováková, C. A. M. van Ginneken, H Verbruggen, C. Haanen	6
18	Reversible coma due to hypokalaemia in a patient treated for acute leukaemia. 1983 ·PubMed ·P. Hupperets, (unknown), (unknown), Andreas Keyser, C. Haanen	1
19	Blastomycosis treated successfully with miconazole. 1979 ·PubMed ·(unknown), C. Haanen	3
20	Platelets in haemostasis 1968 ·S. Karger eBooks ·C. Haanen, (unknown)	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact